FDA Grants 510(k) Clearance for New Class of Photon-Counting CT Scanners
The Naeotom Alpha class of photon-counting computed tomography (PCCT) scanners emphasize significantly reduced scan times and enhanced detection of small abnormalities.
The Food and Drug Administration (FDA) has cleared the Naeotom Alpha class of photon-counting computed tomography (PCCT) scanners, which include the Naeotom Alpha.Prime, the first single-source PCCT scanner.
Offering a scan speed of 345 mm/sec, the Naeotom Alpha.Prime may facilitate enhanced workflow efficiencies for in-patient, emergency room and ambulatory settings, according to Siemens Healthineers, the manufacturer of the Naeotom Alpha class of PCCT scanners.
The Naeotom Alpha class of photon-counting computed tomography (PCCT) scanners, including the first single-source PCCT scanner Naeptom Alpha.Prime, have garnered 510(k) clearance from the FDA. (Images courtesy of Siemens Healthineers.)
The company said the dual-source PCCT scanner Naeotom Alpha.Pro features scan speed up to 491 mm/sec and 66 ms temporal resolution. In addition to being well-suited for pulmonology and pediatric assessments, Siemens Healthineers notes the Naeotom Alpha.Pro offers automated analysis and evaluation of highly calcified coronary arteries.
Rounding out the class is the Naeotom Alpha.Peak (formerly called Naeotom Alpha). The company noted the Naeotom Alpha.Peak offers a scan speed of 737 mm/sec and employs Quantum HD resolution to provide enhanced anatomical detail at a 0.2 mm slice thickness, facilitating detection of small abnormalities.
“By introducing our Naeotom Alpha class of photon-counting CT scanners, Siemens Healthineers delivers on what we see as our responsibility: to broaden the availability of this technology and enable customers to provide its clinical benefits to as many clinicians and patients as possible,” said Matthew Dedman, the head of computed tomography at Siemens Healthineers North America.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
